Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data

Drug Metabolism and Disposition

Volumn 30, Issue 3, 2002, Pages 276-282

  Nestorov, Ivan ^a   Gueorguieva, Ivelina ^a   Jones, Hannah M ^a   Houston, Brian ^a   Rowland, Malcolm ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; FLUNITRAZEPAM; MIDAZOLAM; TRIAZOLAM;

ANALYTIC METHOD; ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; INFORMATION PROCESSING; LIVER CLEARANCE; MEASUREMENT; METHODOLOGY; MONTE CARLO METHOD; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ANIMALS; BENZODIAZEPINES; BIOTRANSFORMATION; COMPUTER SIMULATION; FUZZY LOGIC; HEPATOCYTES; LIKELIHOOD FUNCTIONS; LIVER; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; PHARMACOKINETICS; RATS; REPRODUCIBILITY OF RESULTS;

EID: 0036180830     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.3.276     Document Type: Article

References (33)

1. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat
2. Comparison of three physiologically based pharmacokinetic models of benzene disposition
3. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: Studies with induced livers involving diazepam
4. In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes
5. Vertex method for computing functions of fuzzy variables
6. Fuzzy computations in risk and decision analysis
7. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output
8. Anticonvulsant pharmacodynamics and disposition of triazolam in rats
9. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for pemhlorethylene (PCE)
10. An improved method of performing fuzzy arithmetic for computer vision
11. Uncertainties in pharmacokinetic modeling of perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors
12. Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical simulation model of anticonvulsant effect
13. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
14. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices
15. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
16. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models
17. Regional blood flow in conscious resting rats determined by microsphere distribution
18. Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam
19. The use of human hepatocytes to select compounds based on their expected extraction ratios in humans
20. R) between in vivo and in vitro studies in rat, dog and human
21. Incorporating variability and uncertainty into the in vitro-in vivo prediction of hepatic clearance
22. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
23. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
24. Measurement of the distribution of cardiac output in anaesthetized rats
25. A comparative investigation of hepatic clearance models: Prediction of metabolite formation and elimination
26. Acute inhibition of methadone metabolism by ritonavir: Projection of interindividual variability from in vitro data
27. Prediction of interindividual variability of in vivo metabolic interactions between ritonavir and methadone: Acute vs. long term effects
28. A characterization of the extension principle
29. Uncertainty modelling and fuzzy sets